Follow-on Compounds
In addition to TL32711, TetraLogic Pharmaceuticals has a large library of over 3000 Smac mimetics, both dimer and monomer compounds, for the development of follow-on compounds for oncology and non-oncology indications.
The TetraLogic research team is elucidating new understanding of the role of Smac mimetics in the biological pathways that regulate cell death and resistance to cancer therapies, as well as, the role of the canonical and non-canonical NF-kB pathways in cell survival and B-cell and T-cell immunity. TetraLogic has strong affiliations and collaborations with top cancer centers and leading scientific and medical researchers in the fields of apoptosis and Smac mimetics that support the advancement of the company's programs.